Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Lilly, Merck Sharp & Dohme Corp., NewLink Genetics, and Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Community Practice Connections™: 3rd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application


Release Date: February 28, 2019
Expiration Date: February 28, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: 3rd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application features case-based discussion of the application of immune-based therapies in several tumor types. Interactive clinical vignettes are followed by short video interviews with leading oncology experts, and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians using immunotherapies.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Lilly, Merck Sharp & Dohme Corp., NewLink Genetics, and Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/Ce certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving role in the treatment of cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer
  • Evaluate clinical trial findings on immuno-oncology (I-O) strategies, and how they can be practically applied to the management of cancer in multiple lines of care
  • Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of I-O strategies
  • Describe how common and uncommon adverse events, associated with the use of I-O strategies, can be proactively mitigated and managed
  • Detail important remaining clinical questions in the field and highly anticipated ongoing clinical trials that are evaluating emerging I-O strategies

Faculty, Staff, and Planners' Disclosures

Faculty

Joaquim Bellmunt, MD, PhD
Associate Professor of Medicine, Harvard Medical School
GU Oncology Research Coordinator PSMAR
Director, IMIM-Hospital del Mar Medical Research Institute
Barcelona, Spain
 

Disclosures: Grant/Research Support: Sanofi-Aventis, Novartis, Takeda, Pfizer; Consultant: Genentech, Merck Sharp & Dohme Corp., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pierre-Fabre, Sanofi-Aventis, Astellas, OncoGenex, Janssen

Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Chair, Melanoma Committee at SWOG
Los Angeles, CA

Disclosures: Consultant: Amgen, Bristol-Myers Squibb, Chugai, Genentech, Merck, Novartis, Roche; Shareholder: Advaxis, Arcus, Bioncotech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, IsoPlexis, Rgenix, Lutris, Pact Pharma, Tango Therapeutics, Kite Pharma

Naiyer A. Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Programs
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, NY

Disclosures: Merck, Roche, Novartis, AstraZeneca, Armo Biosciences; Shareholder: Gritstone Oncology

Ezra Cohen, MD, FRCPSC, FASCO
Professor, Division of Hematology/Oncology,
Department of Medicine, UC San Diego
Co-director, San Diego Center for Precision Immunotherapy
Associate Director for Translational Science,
UC San Diego Moores Cancer Center
Co-leader, Solid Tumor Therapeutics Program
Co-director, Head and Neck Cancer Center of Excellence
San Diego, CA

Disclosures: Consultant: Eisai, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/Ce activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By